Ryan Halsted
Stock Analyst at RBC Capital
(4.45)
# 1,045
Out of 5,162 analysts
138
Total ratings
70.6%
Success rate
13.3%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRVA Privia Health Group | Reiterated: Buy | $31 → $32 | $24.60 | +30.08% | 11 | Nov 19, 2026 | |
| MDLN Medline | Reiterated: Buy | $46 | $39.16 | +17.47% | 10 | Nov 11, 2026 | |
| DOCS Doximity | Rated: Buy | $28 → $34 | $30.67 | +10.86% | 12 | Nov 6, 2026 | |
| CAH Cardinal Health | Rated: Buy | $276 → $295 | $278.32 | +5.99% | 4 | Nov 5, 2026 | |
| COR Cencora | Reiterated: Hold | $330 | $348.31 | -5.26% | 4 | Nov 5, 2026 | |
| EVH Evolent Health | Reiterated: Hold | $3 | $3.93 | -23.66% | 8 | Nov 5, 2026 | |
| CRL Charles River Laboratories International | Reiterated: Buy | $322 → $352 | $333.25 | +5.63% | 9 | Nov 4, 2026 | |
| MCK McKesson | Rated: Hold | $845 → $965 | $1,084.43 | -11.01% | 4 | Nov 4, 2026 | |
| SHC Sotera Health Company | Reiterated: Buy | $24 | $16.28 | +47.42% | 12 | Nov 3, 2026 | |
| WAY Waystar Holding | Reiterated: Buy | $44 | $27.54 | +59.77% | 11 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $185 → $226 | $195.16 | +15.80% | 8 | Oct 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $319 | $257.84 | +23.72% | 9 | Oct 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $692 | $646.87 | +6.98% | 8 | Oct 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $24 | $25.10 | -4.38% | 7 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $108 | $97.31 | +10.99% | 5 | Oct 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 | $12.26 | +54.98% | 7 | Oct 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $8.59 | n/a | 4 | Jan 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $32.42 | n/a | 1 | Oct 6, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $71.87 | n/a | 1 | Sep 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $22 | $182.98 | n/a | 3 | May 12, 2016 |
Privia Health Group
Nov 19, 2026
Reiterated: Buy
Price Target: $31 → $32
Current: $24.60
Upside: +30.08%
Medline
Nov 11, 2026
Reiterated: Buy
Price Target: $46
Current: $39.16
Upside: +17.47%
Doximity
Nov 6, 2026
Rated: Buy
Price Target: $28 → $34
Current: $30.67
Upside: +10.86%
Cardinal Health
Nov 5, 2026
Rated: Buy
Price Target: $276 → $295
Current: $278.32
Upside: +5.99%
Cencora
Nov 5, 2026
Reiterated: Hold
Price Target: $330
Current: $348.31
Upside: -5.26%
Evolent Health
Nov 5, 2026
Reiterated: Hold
Price Target: $3
Current: $3.93
Upside: -23.66%
Charles River Laboratories International
Nov 4, 2026
Reiterated: Buy
Price Target: $322 → $352
Current: $333.25
Upside: +5.63%
McKesson
Nov 4, 2026
Rated: Hold
Price Target: $845 → $965
Current: $1,084.43
Upside: -11.01%
Sotera Health Company
Nov 3, 2026
Reiterated: Buy
Price Target: $24
Current: $16.28
Upside: +47.42%
Waystar Holding
Nov 2, 2026
Reiterated: Buy
Price Target: $44
Current: $27.54
Upside: +59.77%
Oct 28, 2026
Rated: Buy
Price Target: $185 → $226
Current: $195.16
Upside: +15.80%
Oct 27, 2026
Reiterated: Buy
Price Target: $319
Current: $257.84
Upside: +23.72%
Oct 22, 2026
Reiterated: Buy
Price Target: $692
Current: $646.87
Upside: +6.98%
Oct 21, 2026
Reiterated: Hold
Price Target: $24
Current: $25.10
Upside: -4.38%
Oct 6, 2026
Reiterated: Buy
Price Target: $108
Current: $97.31
Upside: +10.99%
Oct 6, 2026
Reiterated: Buy
Price Target: $19
Current: $12.26
Upside: +54.98%
Jan 12, 2017
Upgraded: Buy
Price Target: n/a
Current: $8.59
Upside: n/a
Oct 6, 2016
Reiterated: Hold
Price Target: n/a
Current: $32.42
Upside: n/a
Sep 9, 2016
Reiterated: Hold
Price Target: n/a
Current: $71.87
Upside: n/a
May 12, 2016
Reiterated: Hold
Price Target: $22
Current: $182.98
Upside: n/a